Redefining clinical trials: Adopting AI for speed, volume and diversity
IBM Big Data Hub
MAY 6, 2024
The FDA, in its May 2023 draft guidance, backed the adoption of DCTs across drugs, biologics and medical devices , highlighting their merits such as enhanced patient convenience, diminished caregiver burden, broader access to varied demographics, amplified trial productivity, and support for research on rare or mobility-restricted patient groups.
80 
Let's personalize your content